article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 1

Drug Target Review

In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge. Raminderpal earned his PhD in semiconductor modelling in 1997.

RNA 52
article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 2 of 3

Drug Target Review

In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge.

Drugs 69
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The next phase of the multiomics evolution, powered by AI

Drug Target Review

In 2003, the completion of the Human Genome Project was celebrated as the start of a new era in medicine. The problem is not a lack of genetic insight; instead, biological processes operate on a level that goes far beyond genetic sequences.

RNA 72
article thumbnail

The Issue with Reissue: PTE Edition

FDA Law Blog: Biosimilars

Merck applied for a patent term extension on the reissued patent, claiming the start of the regulatory review period as April 2004 and termination at the approval of the BRIDION NDA in December 2015.

article thumbnail

Why radiopharmaceuticals are gaining ground in the fight against cancer

Drug Target Review

He served as Deputy Chair and Chief of Clinical Nuclear Medicine at MD Anderson Cancer Center and founded Excel Diagnostics & Nuclear Oncology Center in 2003. Delpassand is a board-certified nuclear medicine physician with extensive experience in Targeted Radionuclide Therapy and Nuclear oncology.

Therapies 100
article thumbnail

How AI and LLMs are transforming drug discovery: part 1

Drug Target Review

In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry. He was also Vice President and Head of the Microbiome Division at Eagle Genomics Ltd, in Cambridge. Raminderpal earned his PhD in semiconductor modelling in 1997. For more: [link] ; [link] ; [link]

Drugs 69
article thumbnail

Navigating Regulatory Hurdles in Drug Development

DrugBank

Similarly, AstraZeneca’s gefitinib , an early targeted therapy for lung cancer, received a ccelerated approval in 2003 but later faced restricted use when follow-up studies failed to confirm its clinical benefit in a broader patient population.